Last reviewed · How we verify
Polycythemia Vera — Treatment Landscape & Competitive Intelligence
Haematology
5 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Besremi | ROPEGINTERFERON ALFA-2B | Pharma Essentia Corporation | Interferon alfa-2b [EPC] | Interferon alpha/beta receptor | 2021-01-01 | |
| Jakafi | RUXOLITINIB | Incyte Corp | Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV | 2011-01-01 | ||
| Phosphotope | sodium phosphate (32P) | Mallinckrodt | 1959-01-01 | |||
| Valchlor | MECHLORETHAMINE | Recordati | Alkylating Drug [EPC] | 1949-01-01 | ||
| Ropeginterferon | Ropeginterferon | St. Olavs Hospital | Interferon alpha/beta receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Polycythemia Vera
- Incyte Corp · 1 drug in Polycythemia Vera
- Mallinckrodt · 1 drug in Polycythemia Vera
- Pharma Essentia Corporation · 1 drug in Polycythemia Vera
- Recordati · 1 drug in Polycythemia Vera
- St. Olavs Hospital · 1 drug in Polycythemia Vera
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Polycythemia Vera:
- Polycythemia Vera treatment updates — RSS
- Polycythemia Vera treatment updates — Atom
- Polycythemia Vera treatment updates — JSON
Cite this brief
Drug Landscape (2026). Polycythemia Vera — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/polycythemia-vera. Accessed 2026-05-13.
Related
- Polycythemia Vera full disease profile — treatment pathway, diagnostics, guidelines
- Haematology area landing
- Browse all CI briefs
- Build a custom feed